Company: REVB
Filing Date: 2025-01-07
Form Type: 8-K
Source: 0000950170-25-002828
Chunk: 0

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-01-07
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 3, 2025, Revelation Biosciences, Inc. (the “ Company”) received a decision letter issued by the Nasdaq Hearings Panel granting the Company’s request to continue its listing on The Nasdaq Stock Market, subject to effecting a reverse stock split by January 31, 2025 and its stock trading at or above $1.00 for at least ten consecutive trading days by February 14, 2025. The Company intends to file a subsequent Form 8-K to disclose the details of the reverse stock split, including the final split ratio, effective date, and any other material information, once such details are determined by the Board of Directors.

Additionally, the Nasdaq Hearings Panel confirmed that the Company has regained compliance with the Stockholders’ Equity Requirement of Listing Rule 5550(b)(1) for which, as previously disclosed, the Company received a notice of delisting on August 14, 2024.

Item 8.01 Other Events.